Barclays
CAPR icon

Barclays’s Capricor Therapeutics CAPR Stock Holding History

Barclays’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-328,900
Closed -$9.49M – 5076
2025
Q4 		$9.49M Buy
328,900
+244,800
+291% +$3.2M ﹤0.01% 1721
2025
Q3 		$606K Sell
84,100
-10,000
-11% -$73.6K ﹤0.01% 3689
2025
Q2 		$934K Buy
+94,100
New +$994K ﹤0.01% 3387

Other funds holding CAPR

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
HBK Sorce Advisory
HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Barclays's CAPR Position: Q3 2026 in Review

Barclays increased its Capricor Therapeutics (CAPR) stake by 309% in Q3 2026, buying an estimated $2.31M and bringing the position to 275,957 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Barclays first reported a position in CAPR in Q1 2021 and has held it in 13 quarters since. The position peaked at $9.6M in Q1 2026. 62 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Barclays held 275,957 shares of Capricor Therapeutics worth $2.61M as of Q3 2026.
  • Barclays bought 208,517 Capricor Therapeutics shares in Q3 2026, an estimated $2.31M.
  • Capricor Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2435 holding.
  • Barclays first reported a position in Capricor Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Barclays's Capricor Therapeutics position peaked at $9.6M in Q1 2026.
  • 62 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.